Changes Made to Phase 3 Xtandi Trial in Men with Non–Metastatic Castration–Resistant Prostate Cancer

Changes Made to Phase 3 Xtandi Trial in Men with Non–Metastatic Castration–Resistant Prostate Cancer
Astellas Pharma and Pfizer amended the protocol of the international Phase 3 PROSPER trial evaluating Xtandi (enzalutamide) in men with non–metastatic castration–resistant prostate cancer (CRPC). PROSPER is a randomized, double–blind, placebo–controlled trial (
Subscribe or to access all post and page content.